TRVN · Trevena Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $114.0K | $103.0K | $88.0K | - | $175.0K | $88.0K | $127.0K | - | $2.37M | $216.0K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.87M | $3.13M | $3.96M | - | $4.26M | $3.99M | $3.91M | - | $5.27M | $4.29M |
| SG&A | $3.88M | $3.60M | $5.84M | - | $4.57M | $5.14M | $6.09M | - | $7.68M | $10.31M |
| Total Operating Expenses | $5.86M | $6.83M | $9.90M | - | $9.01M | $9.22M | $10.13M | - | $15.32M | $14.81M |
| D&A | - | - | $88.0K | - | - | - | $82.0K | - | - | - |
| Operating Income | ($5.58M) | ($6.50M) | ($9.88M) | - | ($8.83M) | ($6.20M) | ($10.12M) | - | ($15.76M) | ($14.81M) |
| Interest Expense | $1.0K | $521.0K | $513.0K | - | $210.0K | $1.12M | $446.0K | - | $401.0K | $325.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.94M) | ($4.89M) | ($7.68M) | - | ($7.93M) | ($8.01M) | ($7.82M) | - | ($15.29M) | ($14.98M) |
| EPS - Basic | ($5.79) | ($5.75) | ($9.00) | - | ($14.25) | ($17.25) | ($20.25) | - | ($56.25) | ($56.25) |
| EPS - Diluted | ($5.79) | ($5.75) | ($9.00) | - | ($14.25) | ($17.25) | ($20.25) | - | ($56.25) | ($56.25) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.46M | $16.37M | $23.55M | $32.98M | $34.95M | $28.10M | $27.44M | $38.32M | $22.43M | $19.59M |
| Accounts Receivable | - | - | - | - | $179.0K | - | - | - | - | - |
| Inventory | - | - | - | - | $900.0K | $901.0K | $906.0K | $906.0K | $785.0K | $2.99M |
| Accounts Payable | $918.0K | $1.13M | $2.33M | $2.30M | $1.54M | $2.53M | $1.66M | $2.37M | $1.42M | $2.72M |
| Current Assets | $14.73M | $18.03M | $25.98M | $35.20M | $39.48M | $32.97M | $30.77M | $41.01M | $42.54M | $55.78M |
| Total Assets | $19.19M | $22.94M | $31.14M | $40.60M | $45.13M | $38.86M | $38.29M | $48.68M | $51.02M | $64.80M |
| Current Liabilities | $6.09M | $5.21M | $7.21M | $7.55M | $6.16M | $8.18M | $8.02M | $8.73M | $9.26M | $9.51M |
| Long-term Debt | $31.97M | $31.53M | $31.32M | $30.81M | $29.64M | $14.18M | $13.48M | $13.43M | $13.36M | $13.47M |
| Total Liabilities | $42.50M | $41.90M | $45.79M | $48.26M | $41.58M | $29.08M | $28.14M | $33.08M | $29.16M | $28.86M |
| Stockholders' Equity | ($23.31M) | ($18.96M) | ($14.65M) | ($7.66M) | $3.55M | $9.78M | $10.15M | $15.60M | $21.86M | $35.94M |
| Retained Earnings | ($605.57M) | ($600.63M) | ($595.74M) | ($588.06M) | ($571.53M) | ($563.60M) | ($555.59M) | ($547.77M) | ($540.77M) | ($525.47M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($9.42M) | - | - | - | ($10.87M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | ($3.0K) | - | - | - | ($2.0K) | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.7% | -21.3% | -24.7% | - | -17.6% | -20.6% | -20.4% | - | -30.0% | -23.1% |
| Return on equity | 21.2% | 25.8% | 52.4% | - | -223.4% | -81.9% | -77.0% | - | -70.0% | -41.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.42 | 3.46 | 3.60 | 4.66 | 6.41 | 4.03 | 3.84 | 4.70 | 4.60 | 5.87 |
| Quick ratio | 2.42 | 3.46 | 3.60 | 4.66 | 6.27 | 3.92 | 3.72 | 4.59 | 4.51 | 5.55 |
| Cash ratio | 2.21 | 3.14 | 3.27 | 4.37 | 5.68 | 3.44 | 3.42 | 4.39 | 2.42 | 2.06 |
| Leverage | ||||||||||
| Debt / Equity | -1.37 | -1.66 | -2.14 | -4.02 | 8.35 | 1.45 | 1.33 | 0.86 | 0.61 | 0.37 |
| Debt / Assets | 1.67 | 1.37 | 1.01 | 0.76 | 0.66 | 0.36 | 0.35 | 0.28 | 0.26 | 0.21 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5577.0x | -12.5x | -19.3x | - | -42.0x | -5.5x | -22.7x | - | -39.3x | -45.6x |
| Equity multiplier | -0.82 | -1.21 | -2.12 | -5.30 | 12.72 | 3.97 | 3.77 | 3.12 | 2.33 | 1.80 |
| Liabilities / Assets | 2.21 | 1.83 | 1.47 | 1.19 | 0.92 | 0.75 | 0.73 | 0.68 | 0.57 | 0.45 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | 0.19 | 0.10 | 0.14 | - | 3.02 | 0.07 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | 1877d | 3737d | 2604d | - | 121d | 5053d |
| Days payable outstanding | 2939d | 4011d | 9652d | - | 3222d | 10481d | 4782d | - | 218d | 4595d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | 59.3x | 26.1x | 16.5x | - | 746.7x | 1176.1x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.8% | -5.0% | 2.4% | - | 44.0% | 58.2% | 38.5% | - | -13.7% | -5.3% |
| Net income growth (YoY) | 37.7% | 39.0% | 1.8% | - | 48.2% | 46.5% | 52.3% | - | -11.1% | -6.8% |
| EPS growth (YoY) | 59.4% | 66.7% | 55.6% | - | 74.7% | 69.3% | -33650.0% | - | -70212.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -83.8% | -72.8% | -79.4% | -75.9% | -71.9% | -60.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TREVENA INC against the 5 most active filers in the same SIC group.